SharkNinja, Inc. (SN)
(Real Time Quote from BATS)
$103.79 USD
-1.98 (-1.87%)
Updated Sep 23, 2024 11:24 AM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SN 103.79 -1.98(-1.87%)
Will SN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SN
SharkNinja, Inc. (SN) Registers a Bigger Fall Than the Market: Important Facts to Note
SharkNinja, Inc. (SN) is a Great Momentum Stock: Should You Buy?
SN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Investment Ideas feature highlights: SharkNinja, KT and The Progressive
3 Underfollowed Stocks with Unstoppable Momentum (SN, KT, PGR)
All You Need to Know About SharkNinja, Inc. (SN) Rating Upgrade to Strong Buy
Other News for SN
Best And Worst Performers Since August 5, 2024
SN November 15th Options Begin Trading
Best And Worst Performers Since 8/5
First cases using Smith+Nephew?s new CATALYSTEM? Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Barclays Sticks to Its Hold Rating for Smith & Nephew (SN)